Main points:
Review of sector Market:
This week (2.28 ~ 03.04), Shenwan beauty care sector decreased by – 0.88%, which was weaker than the market. The Shanghai Composite Index and the gem index were – 0.11% and – 3.75% respectively. Shenwan beauty care sector lost 0.77 PCT to the Shanghai Composite Index and outperformed the gem index by 2.87 PCT.
Wind medical beauty and cosmetics index: this week, the CSI 300 index was – 1.68%, and the wind medical beauty index was + 1.05%, outperforming the CSI 300 market by 2.73 PCT; The wind cosmetics index was – 0.41%, outperforming the CSI 300 market by 1.27pct.
Industry highlights:
(1) 38 promotion is imminent. According to the e-commerce news, in the pre-sale activity on February 27, Li Jiaqi’s live room was watched by more than 70 million people, with sales of 2.825 billion yuan. This figure is far higher than the 790 million yuan sales jointly created by Li Jiaqi and Weiya in the same period last year. (CBO News)
(2) according to the administrative punishment decision of Guangzhou market supervision and Administration Bureau, Guangzhou shuizhiyu Cosmetics Co., Ltd. was fined 153000 yuan and confiscated 14000 yuan of illegal income for suspected illegal acts such as selling cosmetics produced by production enterprises beyond the scope of license and selling non recorded cosmetics for special purposes. (CBO News)
Company announcement:
Cabio Biotech (Wuhan) Co.Ltd(688089) : the announcement of 2021 annual performance express was issued. In 2021, the company realized an operating revenue of 350 million yuan (YoY + 9%); The net profit attributable to the parent company was 130 million yuan (yoy-2%); The net profit of non parent company deduction was 83.293 million yuan (YoY + 0.9%).
Shanghai Haohai Biological Technology Co.Ltd(688366) : the announcement of 2021 annual performance express was issued. During the reporting period, the company realized an operating revenue of 1.77 billion yuan (YoY + 33%); The net profit attributable to the parent company was 350 million yuan (YoY + 53%); The net profit of non parent company deduction was 330 million yuan (YoY + 58%).
Sihuan medicine: (1) the group’s Meiyan space independently developed four medical skin care dressing products, including medical skin care dressing, medical skin care dressing, medical wet repair dressing and medical wet repair dressing, which have obtained the class II medical device registration certificate issued by the State Drug Administration. (2) The listing application of jiaglijing new drug of Huisheng biology, a non wholly-owned subsidiary of the group, has been accepted by the State Food and drug administration. It is the second domestic class 1 innovative drug sglt-2 inhibitor to apply for listing in China and accepted.
Huadong Medicine Co.Ltd(000963) : Announcement on the signing of equity investment agreement and product exclusive license agreement between the wholly-owned subsidiary and Heidelberg Pharma, Germany, Huadong Medicine Co.Ltd(000963) investment holding (Hong Kong) obtained 35% equity, with an equity investment amount of 105 million euros; The exclusive rights and interests of hdp-101 in the development and commercialization of hdp-101 in China and the United States, including the exclusive license of hdp-103 in China and the United States.
Investment advice
(1) cosmetics industry: the overall sales of Amoy skin care in February were boosted, and Gmv increased by 30% year-on-year in February; Winona, Proya Cosmetics Co.Ltd(603605) , Dr. Chen ER and Yilian continued to sell beautifully. Amoy cosmetics market sales fell 10% year-on-year in February. The sales of Mao Geping and Caitang continued to rise. Strong products + strong brands bring the possibility of breaking the brand circle, and continue to pay attention to the head cosmetics brand with strong R & D ability and brand strength. Attention: [ Yunnan Botanee Bio-Technology Group Co.Ltd(300957) ] subdivide the leader in the field of sensitive muscle skin care; [ Proya Cosmetics Co.Ltd(603605) ] diversified high-quality brands; [ Shanghai Jahwa United Co.Ltd(600315) ] multi category development and continuous innovation to create new items; [ Guangdong Marubi Biotechnology Co.Ltd(603983) ] focuses on medium and high-end, with rich marketing and distribution channels; [ Syoung Group Co.Ltd(300740) ] strong operation capacity and gradual improvement of category structure;
(2) medical beauty industry: the demand side of the medical beauty industry continues to expand, the supply side products are more diversified, and the policy side strengthens the supervision of medical beauty institutions and medical beauty products. We are optimistic about upstream medical and American enterprises with class III medical device certificate and perfect product matrix layout and downstream medical institutions with long-term standardized operation. Attention: [ Bloomage Biotechnology Corporation Limited(688363) ] local hyaluronic acid raw material leader; The difference between the appearance of children and the appearance of children is more satisfied; [ Huadong Medicine Co.Ltd(000963) ] overall layout of medical beauty business; [ Shanghai Haohai Biological Technology Co.Ltd(688366) ] integration of R & D, production and sales; [Sihuan medicine] botulinum toxin + double antibody go hand in hand; Pay attention to Lancy Co.Ltd(002612) etc. of the layout of downstream medical and aesthetic institutions.
Risk tips
The risk of intensified industry competition; Uncertainty of industrial regulatory policies; Macroeconomic fluctuations, etc.
